in Newswire May 3, 2019

Class Action: Combivent Respimat Asthma Inhaler Contains Far Fewer Doses Than Advertised [UPDATE]

by Corrado Rizzi

Last Updated on October 7, 2020

Ignacuinos v. Boehringer Ingelheim Pharmaceuticals, Inc.

Filed: May 3, 2019 § 3:19-cv-00672

A COPD sufferer alleges Boehringer Ingelheim's Combivent Respimat asthma inhaler contains far fewer than the 120 doses promised in the advertising and marketing of the treatment.

Law(s)

State(s)

Connecticut

Case Updates

October 8, 2020 – Lawsuit Dismissed

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on October 7, 2020 — 2:10 PM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Managing Editor and a writer for ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.